All News about Gilead Sciences
![](https://mms.businesswire.com/media/20240904599708/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Unveiling 10 Analyst Insights On Gilead Sciences
September 04, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/09/03/Merck--Gilead.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
September 03, 2024
Via Benzinga
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Peering Into Gilead Sciences's Recent Short Interest
August 20, 2024
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2019/05/Stock-drugMedicine-03-adobe.jpg)
![](https://mms.businesswire.com/media/20240821963609/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences to Present at Upcoming Investor Conferences
August 21, 2024
Via Business Wire
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/08/16/GileadSciences-Shutterstock.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
August 15, 2024
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2018/04/Stock-Gilead-02-Shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/08/15/GileadSciences-Shutterstock.jpeg?width=1200&height=800&fit=crop)
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
Via Benzinga
Exposures
Product Safety
![](https://mms.businesswire.com/media/20240814469557/en/2216157/22/GSI_Livdelzi_58.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/defensivestocks1600.png)
![](https://g.foolcdn.com/editorial/images/786551/getty-couple-high-five-happy.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/08/09/GileadSciences-Shutterstock.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/08/09/WallStreet-NYSE.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
August 08, 2024
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://investorplace.com/wp-content/uploads/2019/07/gild1600.jpg)
![](https://mms.businesswire.com/media/20240807993584/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences Announces Second Quarter 2024 Financial Results
August 08, 2024
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2024/08/08/Wall-Street.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/08/08/Wall-Street-US-stocks.jpeg?width=1200&height=800&fit=crop)
![](https://talkmarkets.com/images/logos/talkmarkets.png)
![](https://g.foolcdn.com/editorial/images/785210/person-sitting-at-a-desk-looking-at-two-monitors.jpg)
![](https://investorplace.com/wp-content/uploads/2019/07/nasdaq-building-blue.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.